RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Example of details involved in acquisition talks: like ONCY actually Azzak, I wouldn't say the science is 'unequivocal' yet... remember, even for this PanCan trial, the go/no go decision won't be until early 2025. That means precisely that there is still great risk here... For the past five years, every trial ONCY has conducted has not been powered to show statistical signifiance.
It's a glaring error in management I think, but probably calculated, because as of yet the data remains, hopeful... and that is what Matt and Co continue to tout... hope.
The Ph III mBC trial that was not started 5 years ago, was delayed so they could check with a triplet using a CPI - the claim being to reduce trial tiime... hmmmm, I wonder how that went.
This company has already failed one Phase III, so they tread very carefully, because another failure would destroy all credibility... this is STILL a risky investment. And that probably explains the lack of BP interest.